Experienced in Diencephalic Syndrome

Dr. Christian A. Thomas

Hematology Oncology | Hematology | Oncology
Maine Center For Cancer Medicine And Blood Disorders PA
155 Borthwick Ave, Suite C, 
Portsmouth, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Diencephalic Syndrome
Maine Center For Cancer Medicine And Blood Disorders PA
155 Borthwick Ave, Suite C, 
Portsmouth, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christian Thomas is a Hematologist Oncology specialist and a Hematologist in Portsmouth, New Hampshire. Dr. Thomas is rated as an Experienced provider by MediFind in the treatment of Diencephalic Syndrome. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Lung Cancer, and Nephrectomy.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NH
Hospital Affiliations
Mainehealth Maine Medical Center
The Memorial Hospital
Mainehealth Pen Bay Hospital
Northern Light Mercy Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MAINE CENTER FOR CANCER MEDICINE AND BLOOD DISORDERS PA
155 Borthwick Ave, Suite C, Portsmouth, NH 03801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: August 16, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
Enrollment Status: Completed
Publish Date: April 13, 2023
Intervention Type: Drug
Study Drug: VPM1002BC
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

18 Total Publications

Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Journal: NPJ precision oncology
Published: June 11, 2023
Similar Doctors
Experienced in Diencephalic Syndrome
Dr. Danny M. Sims
Hematology Oncology | Oncology
Experienced in Diencephalic Syndrome
Dr. Danny M. Sims
Hematology Oncology | Oncology
200 Technology Dr, 
Hooksett, NH 
 (33.8 miles away)
603-622-6484
Languages Spoken:
English
See accepted insurances

Danny Sims is a Hematologist Oncology specialist and an Oncologist in Hooksett, New Hampshire. Dr. Sims is rated as a Distinguished provider by MediFind in the treatment of Diencephalic Syndrome. His top areas of expertise are Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Chronic Lymphocytic Leukemia (CLL), and Lung Cancer.

Experienced in Diencephalic Syndrome
Dr. Douglas D. Tisdale
Hematology Oncology | Oncology
Experienced in Diencephalic Syndrome
Dr. Douglas D. Tisdale
Hematology Oncology | Oncology

Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is

1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C, 
Newburyport, MA 
 (18.1 miles away)
978-463-1374
Languages Spoken:
English
See accepted insurances

Douglas Tisdale is a Hematologist Oncology specialist and an Oncologist in Newburyport, Massachusetts. Dr. Tisdale is rated as a Distinguished provider by MediFind in the treatment of Diencephalic Syndrome. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thomas's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 30 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile